Several analysts have written on the stock recently. In a research report on Tuesday, November 5, Barclays assumed reporting on Vir Biotechnology stock. We set a stock "overweight" score and a price target of $25.00. In a research report on Wednesday, November 13, Robert W. Baird assumed coverage of Vir Biotechnology shares. They set on stock a "neutral" rating. In a research report on Tuesday, November 5, JPMorgan Chase &a....
Tags : Barclays, ,
comments (0)